Stay informed with the latest updates for the inheritable blood disorders community. Industry Takeda's Voluntary Withdrawal: Alert on Misprinted Labels for VONVENDI®Jan 26, 2024 Industry FDA Accepts Biologics License Application for MarstacimabDec 14, 2023 Industry CSL Presents Three Year Treatment Data for Hemophilia B Gene TherapyDec 12, 2023 Industry FDA Grants Expanded Approval to Wilate® for Prophylaxis in All Types of…Dec 5, 2023 Industry First Patient Dosed with Hemophilia Gene Therapy Candidate ASC618Dec 4, 2023 Industry Sernova Receives Dual FDA Designations for Investigational Hemophilia…Nov 29, 2023 Industry Investigational T-Cell Therapy for Hemophilia A…Oct 12, 2023 Industry New Trial Data Shows ALTUVIIIO™ Prophylaxis Effective in ChildrenJul 3, 2023 Industry Hemophilia A Gene Therapy Product Receives U.S. FDA ApprovalJun 30, 2023 Industry First Hemophilia B Patient Dosed with Gene Therapy ProductJun 20, 2023 Industry Pfizer Highlights Phase 3 Trial Results of Marstacimab May 31, 2023 Industry FDA Requests Additional Information on Concizumab from Novo Nordisk May 5, 2023 Industry Sanofi Announces Publication of Two Phase 3 Fitusiran TrialsApr 6, 2023 Industry BioMarin Announces FDA’s Extended Review of Investigational…Mar 10, 2023 Industry uniQure Announces Published Trial Results for Approved Gene TherapyFeb 27, 2023 Pagination First page Previous page Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Last page